Jpmorgan Chase & CO Exelixis, Inc. Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Exelixis, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 951,185 shares of EXEL stock, worth $36.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

951,185

Previous 3,314,575 71.3%

Holding current value

$36.6 Million

Previous $110 Million 68.18%

% of portfolio

0.0%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$32.38 - $39.16 $76.5 Million - $92.6 Million	-2,363,390 Reduced 71.3%	951,185 $35.1 Million
Q4 2024 Feb 12, 2025	SELL	$25.39 - $36.46 $28.3 Million - $40.7 Million	-1,116,078 Reduced 25.19%	3,314,575 $110 Million
Q3 2024 Dec 26, 2024	SELL	$21.96 - $27.6 $13.6 Million - $17.1 Million	-618,203 Reduced 12.24%	4,430,653 $115 Million
Q3 2024 Nov 08, 2024	SELL	$21.96 - $27.6 $13.6 Million - $17.1 Million	-618,203 Reduced 12.24%	4,430,653 $115 Million
Q2 2024 Dec 26, 2024	BUY	$20.34 - $23.73 $12.6 Million - $14.7 Million	618,203 Added 13.95%	5,048,856 $113 Million
Q2 2024 Aug 12, 2024	SELL	$20.34 - $23.73 $5.59 Million - $6.53 Million	-275,003 Reduced 5.17%	5,048,856 $113 Million
Q1 2024 Dec 26, 2024	BUY	$20.17 - $23.93 $18 Million - $21.4 Million	893,206 Added 20.16%	5,323,859 $126 Million
Q1 2024 May 10, 2024	SELL	$20.17 - $23.93 $48.8 Million - $57.9 Million	-2,417,730 Reduced 31.23%	5,323,859 $126 Million
Q4 2023 Dec 26, 2024	BUY	$19.25 - $24.13 $63.7 Million - $79.9 Million	3,310,936 Added 74.73%	7,741,589 $186 Million
Q4 2023 Feb 12, 2024	BUY	$19.25 - $24.13 $1.8 Million - $2.25 Million	93,368 Added 1.22%	7,741,589 $186 Million
Q3 2023 Nov 14, 2023	SELL	$19.04 - $22.74 $903,390 - $1.08 Million	-47,447 Reduced 0.62%	7,648,221 $167 Million
Q2 2023 Aug 11, 2023	SELL	$18.17 - $20.48 $1.25 Million - $1.41 Million	-68,779 Reduced 0.89%	7,695,668 $147 Million
Q1 2023 May 18, 2023	BUY	$16.3 - $19.41 $9.08 Million - $10.8 Million	557,058 Added 7.73%	7,764,447 $151 Million
Q1 2023 May 11, 2023	SELL	$16.3 - $19.41 $86.6 Million - $103 Million	-5,312,565 Reduced 42.43%	7,207,389 $140 Million
Q4 2022 Feb 13, 2023	BUY	$14.96 - $17.39 $2.55 Million - $2.96 Million	170,325 Added 1.38%	12,519,954 $201 Million
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $3.15 Million - $4.47 Million	200,726 Added 1.65%	12,349,629 $194 Million
Q2 2022 Aug 11, 2022	BUY	$17.44 - $23.16 $1.78 Million - $2.37 Million	102,300 Added 0.85%	12,148,903 $253 Million
Q1 2022 May 11, 2022	BUY	$17.03 - $22.67 $1.76 Million - $2.34 Million	103,192 Added 0.86%	12,046,603 $273 Million
Q4 2021 Feb 10, 2022	BUY	$15.84 - $21.88 $8.15 Million - $11.3 Million	514,336 Added 4.5%	11,943,411 $218 Million
Q3 2021 Nov 12, 2021	BUY	$16.3 - $21.14 $186 Million - $242 Million	11,429,075 New	11,429,075 $242 Million

Others Institutions Holding EXEL

# of Institutions

688

Shares Held

260M

Call Options Held

1.41M

Put Options Held

1.55M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $12.4B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Exelixis, Inc. Transaction History